177Lu-PSMA I&T 放射性核素治疗转移性去势抵抗性前列腺癌的剂量计算与剂量-效应关系
本研究纳入22例转移性去势抵抗性前列腺癌患者,分析177Lu-PSMA I&T治疗中剂量学量与生物标志物的相关性。平均注射活度为7416±218 MBq,共评估259个相关性,仅37个具有统计学显著性,其中26个与器官吸收剂量和碱性磷酸酶下降相关。尽管肿瘤分子体积大幅缩小,但剂量-效应相关性缺乏,作者呼吁采用基于SPECT/CT的体素剂量学进一步研究。
要点
- 骨、淋巴结和肝脏病灶的平均肿瘤分子体积分别缩小32.3%、84.7%和72.9%。
- 259个相关性中仅37个有统计学显著性,26个与器官吸收剂量和碱性磷酸酶下降相关。
- 作者呼吁采用基于SPECT/CT的体素剂量学研究以进一步评估剂量-效应关系。
核心结论
- 尽管177Lu-PSMA I&T治疗使mCRPC患者的肿瘤分子体积大幅缩小,但剂量学量与生物标志物变化之间缺乏相关性,作者呼吁采用基于SPECT/CT的体素剂量学研究。
研究设计与样本
- 研究纳入22例接受177Lu-PSMA I&T放射性核素治疗的转移性去势抵抗性前列腺癌患者,患者年龄范围为74±7岁,平均注射活度为7416±218 MBq。
- 将第一个治疗周期后7种不同生物标志物的变化与计算的器官及TMV吸收剂量进行相关性分析,共评估259个相关性。
主要发现
- 在骨、淋巴结和肝脏组织中识别出63个TMV,平均缩小分别为32.3%、84.7%和72.9%。
- 腮腺、肾脏和肝脏的单位 administered activity 吸收剂量分别为0.77、0.71和0.27 mGy/MBq,骨、淋巴结和肝脏恶性肿瘤分别为4.38、5.47和4.95 mGy/MBq。
- 259个可能的相关性中仅37个具有统计学显著性,其中26个与器官吸收剂量和碱性磷酸酶下降相关。
局限性
- 作者指出缺乏相关性,呼吁采用基于SPECT/CT的体素剂量学研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Dose response of 22 patients experiencing mCRPC (metastatic castration-resistant prostate cancer) to Lu-PSMA I&T radionuclide therapy was investigated. Dosimetry calculations are used to assess correlations between dosimetric quantities and biomarker values. METHODS: The patients' age range was 74 ± 7 years at the time of the investigated treatment cycle, and the mean injected activity was 7416 ± 218 MBq. Planar images at several time points postinjection were used for evaluation of absorbed doses to organs and lesion. Ga-PSMA PET/CT follow-up imaging enabled the determination of individual tumor molecular volume (TMV) shrinkage. Changes in 7 different biomarkers after the first treatment cycle were correlated with the calculated absorbed organ and TMV doses, resulting in a total number of 259 investigated correlations. RESULTS: Sixty-three TMVs were identified in the bone, lymph node, and liver tissue with an average reduction of 32.3%, 84.7%, and 72.9%, respectively. Absorbed doses per unit of administered activity for organs and lesions show good agreement with previous works (0.77, 0.71, and 0.27 mGy/MBq for parotid gland, kidneys, and liver as well as 4.38, 5.47, and 4.95 mGy/MBq for bone, lymph node, and liver malignancies, respectively). Only 37 of 259 possible correlations turned out to be statistically significant, 26 of which are associated with the absorbed dose of an organ and the decrease of alkaline phosphatases. CONCLUSIONS: Although treatment with Lu-PSMA I&T leads to a big reduction of TMV in patients with mCRPC, the lack of correlations calls for studies using voxel-wise dosimetry based on SPECT/CTs.
引用
- Barna S, Haug AR, Hartenbach M, et al. Dose Calculations and Dose-Effect Relationships in 177Lu-PSMA I&T Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer. Clin Nucl Med. 2020. PMID: 32604113. doi:10.1097/RLU.0000000000003157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。